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Parkinson Disease (PD) is a progressive neurodegenerative disorder with limited therapeutic
options. In this issue of Cell, Martin et al. link PD protein leucine-rich repeat kinase 2 (LRRK2) to
abnormalities of translational control, a pathogenic mechanism implicated in an increasing number
of CNS neurodegenerative diseases, as well as in normal aging.No therapies exist to halt the relentless
neurodegeneration of Parkinson disease
(PD), an increasingly common disorder
of aging estimated to affect 7–10 million
people worldwide. The initial symptoms
of slowed movement, stiffness, and
tremor caused by degeneration of mid-
brain dopaminergic neurons are treated
by dopamine replacement therapy. Yet
progressive neurodegeneration inevitably
leads to debilitating treatment-resistant
symptoms such as falls and dementia.
Development of therapies requires an
improved understanding of disease
mechanisms at the cellular and molecular
level.
A flurry of genetic discoveries begin-
ning in 1997 has yielded increasing insight
into the molecular underpinnings of PD
(Cookson and Bandmann, 2010). Among
the key PD genes—including SNCA
(encoding a-synuclein), PARKIN, DJ-1,
PINK1, enthusiasm is particularly high
for LRRK2. Dominantly-inherited LRRK2
missense mutations are the most com-
mon genetic cause of PD, accounting for
up to 20% of PD in select clinical samples
like Ashkenazi Jews, and LRRK2-related
PD is typically indistinguishable from spo-
radic disease clinically and neuropatho-
logically. Further, LRRK2 contains kinase
and GTPase domains, enzymatic activ-
ities tractable to therapeutic targeting.
Despite intense interest and extensive
study, the mechanisms through which
LRRK2 mutations cause neurodegenera-
tion are unclear. The best-characterized
mutations fall within the kinase andGTPase domains and the most common,
G2019S, alters the essential Asp-Phe-
Gly (‘‘DFG’’) kinase regulatory motif,
enhancing its activity. Importantly, several
studies report that suppressing kinase
function blocks neurotoxicity. Putative
substrates, including eukaryotic initia-
tion factor 4E (eIF4E)-binding protein
(4E-BP), endophilin A, and ezrin/radixin/
moesin, have yet to be comprehensively
validated, particularly in PD patient tis-
sues. Confusingly, LRRK2 has been local-
ized to and proposed to affect nearly
all cellular compartments. Nevertheless,
an emerging area of focus is the role of
LRRK2 in endolysosomal and autophagic
pathways. This work is of particular inter-
est because dysfunction of these path-
ways is an increasingly recognized theme
of PD (and Alzheimer disease) pathogen-
esis encompassing the action of several
PD-linked proteins (Trinh and Farrer,
2013).
Translation control is another area
where a role for LRRK2 is attracting
growing interest. Eukaryotic translation
consists of three steps: initiation, elonga-
tion, and termination (Sonenberg and
Hinnebusch, 2009). Translational initiation
is a particularly critical step, being rate
limiting and tightly controlled by diverse
signals reflecting cellular energy balance
and stress. Two types of translation initia-
tion exist: cap dependent and cap inde-
pendent. The great majority translational
initiation is cap dependent, controlled by
initiation factors binding to the ‘‘cap’’ at
the 50 end of mRNA. eIF4E binding is aCellcritical step, but is blocked by 4E-BP.
Phosphorylation of 4E-BP releases it
from eIF4E, enabling translational initia-
tion. Less frequently, translational initia-
tion occurs independent of the cap, with
assembly of the ribosome and initiation
factors at an internal ribosomal entry
site (IRES). IRES-mediated translation is
believed to occur when cap-dependent
translation is compromised, such as
during stress and apoptosis. Studies
in Drosophila suggest that PD mutant
LRRK2 causes neurodegeneration by hy-
perphosphorylating 4E-BP, an effect that
can be suppressed by 4E-BP overexpres-
sion (Imai et al., 2008). 4E-BP phosphory-
lation by LRRK2 is also proposed to
enhance translation by disrupting the
miRNA pathway through an abnormal
interaction with Argonaute (Gehrke et al.,
2010).
The report by Martin et al. (2014) in this
issue of Cell adds considerable support
for the possibility that LRRK2 kinase func-
tion enhances translation but points to a
distinct mechanism not involving 4E-BP.
The authors first identified LRRK2 kinase
substrates using a tandem affinity purifi-
cation scheme that yielded several cate-
gories of LRRK2 interactors, including
one featuring ribosomal proteins. After
obtaining additional data supporting ribo-
somal proteins as potential substrates,
they systematically purified 67 ribosomal
proteins, subjecting them to LRRK2 ki-
nase assays. Nineteen of these proteins
could be phosphorylated by LRRK2, three
of which were components of the 40S157, April 10, 2014 ª2014 Elsevier Inc. 291
Figure 1. Stimulation of Translation by the Parkinson Disease Protein LRRK2
Martin et al. demonstrate that PD mutant forms of LRRK2 increase phosphorylation of the 40S ribosomal subunit s15, which increases global translation and
neurodegeneration. PDmutant forms of LRRK2 stimulate both cap-dependent (shown here) and cap-independent (not shown) forms of translation. M7G =mRNA
methylguanosine ‘‘cap’’. The phosphorylation of s15 may enhance translation through several mechanisms, including stimulation of the initiator methionine tRNA
(Met-tRNAi) to 40S, enhanced binding of 40S to the eIF4F initiation, or enhanced scanning for the AUG. eIF4F is a complex of three proteins, eIF4G, eIF4A,
and eIF4E. A key point of control of translational initiation is formation of the eif4F complex (not shown). eIF4F formation is blocked by 4E-BP binding to eIF4E, but
this interaction is inhibited by 4E-BP phosphorylation. Previous work suggests that 4E-BP is a LRRK2 kinase substrate, but such an effect was not observed in
Martin et al.ribosomal small subunit and exhibited
enhanced phosphorylation by G2019S-
LRRK2.
After successfully mapping the phos-
phorylation sites for two of these pro-
teins (s11 and s15), the authors asked
whether nonphosphorylatable versions
(threonine to alanine mutations) could
block G2019S-LRRK2-induced neurode-
generation in cultured neurons. Themuta-
tion in s15 (T136A), but not those in
s11, was protective, and expressing a
‘‘phospho-mimetic’’ T136D s15 molecule
was itself toxic to neurons. Similar results
were obtained in human ES-derived neu-
rons, where knockdown of s15 provided
partial but significant suppression of
G2019S-LRRK2 toxicity. Critically, s15
was found to be hyperphosphorylated in
postmortem brain protein lysates from
PD subjects with the G2019S LRRK2
mutation. Seeking additional evidence,
the authors turned to in vivo studies in
Drosophila. Consistent with the previous
data, they found the phosphorylation of
s15 to be decreased in dLRRK null flies
and increased in flies overexpressing
human G2019S-LRRK2. Remarkably, yet
surprising given the many other functions
ascribed to LRRK2, overexpression of
T136A s15 rescued essentially completely
the climbing and dopamine neurodegen-292 Cell 157, April 10, 2014 ª2014 Elsevier Inerative phenotypes in aged G2019S-
LRRK2 transgenic flies.
These data alone would represent the
best-characterized LRRK2 kinase sub-
strate linked to neurodegeneration, but
the authors pushed further, exploring the
effects of s15 phosphorylation on transla-
tion. Using a bicistronic reporter system
in cell culture, they observed a kinase-
dependent enhancement of both cap-
dependent and cap-independent transla-
tion induced by G2019S-LRRK2. Similar
to its ability to block neurodegeneration
in neuronal culture and Drosophila, coex-
pression of T136A s15 blocked reporter
activation by G2019S-LRRK2, including
when tested in neuronal culture. To
demonstrate definitely in vivo transla-
tional upregulation and its role in neurode-
generation, the authors showed a global
increase of newly synthesized proteins
in G2019S-LRRK2 Drosophila pulse fed
35S, enrichment of mRNAs in heavy poly-
somes in such animals, and suppression
of neurodegeneration in G2019S-LRRK2
Drosophila treated with low dose aniso-
mycin to suppress translation.
While consistent with previous studies
connecting LRRK2 kinase activity to
enhanced translation, these experiments
uniquely extend such observations to
mammalian neurons and provide supportc.for the s15 hyperphosphorylation mecha-
nism in human PD brain lysates. The
identification of a ribosomal protein as a
direct LRRK2 target is striking, raising a
range of mechanistic questions of poten-
tial therapeutic relevance, including how
phospho-s15 mediates this effect (Fig-
ure 1). Little is known about s15, and the
somewhat unexpected increase in both
cap-dependent and cap-independent
translation make this protein particularly
intriguing. Potentially relevant to this
observation is a report implicating s15 in
the nuclear export of preribosomal RNA
(Rouquette et al., 2005). The conclusions
regarding the two modes of translation
initiation rest largely on a bicistronic re-
porter assay. The relationship between
thesemodes of translation is incompletely
understood, as is the nature of mamma-
lian IRES elements. It will be useful to
further explore these findings using addi-
tional methods, including luciferase-
based assays that provide quantitative
measurements over a greater dynamic
range. Such studies may also clarify
the lack of effect seen for 4E-BP or
Argonaute/Dicer proteins on LRRK2-
enhanced translation.
Mechanistic issues aside, the consis-
tent finding of translational activation
by LRRK2 PD mutations is exciting,
potentially linking pathogenesis of this
age-related disease to a key aging-
related pathway. Translational suppres-
sion (via mTOR inhibition and 4E-BP
dephosphorylation) is a major conse-
quence of caloric restriction or rapamycin
treatment, interventions that extend life-
span in yeast, fly, worm, and mouse
(Kennedy and Kaeberlein, 2009). Also
fascinating is the potential convergence
between LRRK2’s roles in translation
and endolysosomal function. Intriguingly,
a recent pair of reports in Cell describes
the dynamic localization of mTOR regula-
tory machinery to the lysosome (Deme-
triades et al., 2014; Menon et al., 2014),
an organelle strongly implicated in PD
pathogenesis. Speculatively, LRRK2 PD
mutations may disrupt the integration or
transfer of information about cellular en-
ergy state, a critical determinant of trans-
lational control. As Martin et al. note,
abnormalities of translational machinery
have recently been discovered as themost common genetic cause of amyotro-
phic lateral sclerosis, and related de-
fects underlie Fragile X-related disorders,
where aberrant transcripts appear impor-
tant in disease pathogenesis. Ultimately,
one hopes that the findings of Martin
et al. will lead to the identification ofmisre-
gulated translational events that will be
tractable therapeutic targets against the
neurodegeneration of PD.ACKNOWLEDGMENTS
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